Santucci Aimee K, Gold Melanie A, Akers Aletha Y, Borrero Sonya, Schwarz Eleanor Bimla
Center for Research on Health Care, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Birth Defects Res A Clin Mol Teratol. 2010 Jan;88(1):64-9. doi: 10.1002/bdra.20618.
This qualitative study explored women's experiences with counseling about medication-induced birth defects, as well as how and when they would like to receive information on medication-induced birth defects from their health care providers (HCPs).
We conducted four focus groups with 36 women of reproductive age (18-45 years old) in Pittsburgh, Pennsylvania. Twenty-one women were using medications to treat a chronic health condition, and two were pregnant. Content analysis was performed by three independent coders using a grounded theory approach. Discrepancies were resolved by consensus.
Women reported depending on their HCPs for information about the risks of teratogenic effects of medications on a pregnancy, but felt the information they had been provided was not always comprehensive. Women want HCPs to initiate discussions about potentially teratogenic medications at the time the medications are prescribed, regardless of whether the woman is sexually active or planning a pregnancy. Women want clear information about all potential outcomes for a fetus. Factors women reported as being critical to effective teratogenic risk counseling included privacy, sufficient time to discuss the topic, and a trusting relationship with their HCP.
Women of reproductive age think that providing information about the possible teratogenic effects of medications could be improved by routine discussions of teratogenic risks at the time medications are prescribed.
本定性研究探讨了女性在接受药物致畸性咨询方面的经历,以及她们希望如何以及何时从医疗保健提供者(HCPs)处获得有关药物致畸性的信息。
我们在宾夕法尼亚州匹兹堡对36名育龄女性(18 - 45岁)进行了四个焦点小组访谈。21名女性正在使用药物治疗慢性健康状况,其中两名怀孕。由三名独立编码员采用扎根理论方法进行内容分析。通过共识解决分歧。
女性报告称依赖医疗保健提供者获取有关药物对妊娠致畸风险的信息,但觉得所提供的信息并不总是全面的。女性希望医疗保健提供者在开药时就开始讨论潜在致畸药物,无论该女性是否有性行为或正在计划怀孕。女性希望获得关于胎儿所有潜在结局的清晰信息。女性报告称对有效的致畸风险咨询至关重要的因素包括隐私、有足够时间讨论该话题以及与医疗保健提供者的信任关系。
育龄女性认为,通过在开药时常规讨论致畸风险,可以改善关于药物可能致畸作用的信息提供。